Amazon Explores AI Content Marketplace With Media Publishers 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
WALTHAM, Mass., Feb. 20, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 27, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 5496159
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 5496159
A telephone replay will be available from approximately 11:00 a.m. ET on February 27, 2018 through midnight on March 5, 2018.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
